KOL Perspectives Selective JAK inhibitors in IBD Report Updated 05012018...
KOL Perspectives Selective JAK inhibitors in IBDSummaryThis KOL Insight briefing focuses on KOLs views of selective JAK inhibitors in IBD.The briefing includes analysis of KOL opinion on the following...
View ArticleCompetitor Landscape Inflammatory Bowel Disease IBD Report Updated 28092018...
Competitor Landscape Inflammatory Bowel Disease IBDSummarySociable Pharma's Treatment Landscape' contains evaluations of ongoing development activities within the IBD market analysis of current...
View ArticleuBiome to Sponsor First Annual Microbiome Conference at 2019 World Economic...
The leader in microbial genomics and 2019 Technology Pioneer announces the worlds first Microbiome Conference at WEF at the 2019 World Economic Forum Annual Meeting.SAN FRANCISCO PRWEB January 01 2019...
View ArticleKOL Perspectives Patient Niches in IBD Report Updated 11092018 Prices from...
KOL Perspectives Patient Niches in IBDSummaryThis KOL Insight briefing focuses on KOLs views of Patient Niches in IBD.Questions topics Perceptions on patient niches and treatments of fistulizing...
View ArticleConnect Biopharmaceuticals Completes $55 Million Series B Financing to...
TAICANG SUZHOU China Jan. 3 2019 PRNewswire Connect Biopharmaceuticals a clinicalstage company that discovers and develops novel immune modulators for the treatment of autoimmune diseases and...
View ArticleModified Exclusive Enteral Nutrition for Treating Crohn Disease Not Ready for...
Early study results are intriguing but not conclusive.
View ArticlePfizer Initiates Phase 2b3 Clinical Trial for PF06651600 an Oral JAK3...
Pfizer Inc. NYSE PFE announced today the initiation of a Phase 2b3 clinical trial for its oral JAK3 inhibitor PF06651600 for the treatment of patients with moderate to severe alopecia areata a chronic...
View ArticleConnect Biopharma of Suzhou Raises $55 Million for Immune Disease Therapies
Connect Biopharma a clinicalstage Suzhou company completed a $55 million Series B financing to support clinical trials of immune modulators for autoimmune diseases. Connect is currently conducting two...
View Article2019 May See New Approach to Refractory Crohn's
MedPage Today Stem cell transplant now in trials for rebooting immune system
View ArticleCrohn's Disease Dynamic Market Forecast to 2026 Report Updated 31102018...
Crohn's Disease Dynamic Market Forecast to 2026SummaryCrohn's disease is a form of inflammatory bowel disease which is comprised of two chronic autoimmune diseases that cause intestinal inflammation...
View ArticleJanssen Submits Application to European Medicines Agency Seeking Approval of...
If approved ustekinumab will be the first interleukin IL1223 inhibitor licensed for the treatment of ulcerative colitis The Janssen Pharmaceutical Companies of Johnson & Johnson announced today...
View ArticleCelgene Corporation Announces 2019 Financial Guidance and Key Milestones
Company achieved its latest fullyear 2018 guidance; will report Q4 2018 results on January 31 2019 Provides fullyear 2019 guidance and reaffirms 2020 outlook Fedratinib NDA and REVLIMIDÂ AUGMENT ...
View ArticleLandos Biopharma Announces Final Safety Results from Phase 1 Study of BT11 in...
BT11 was safe and welltolerated at all doses evaluated and supports initiation of Phase 2 program in IBD patients in 1st half of 2019 Landos Biopharma Inc. an emerging clinicalstage biopharmaceutical...
View ArticleGenerex Biotechnology Completes Acquisition of Regentys Corporation
Announces closing of 51 acquisition of regenerative medicine company Regentys Regentys Extracellular Matrix Hydrogel for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases ...
View ArticleKOL Perspectives Perception of mirikizumab in moderatetosevere UC Report...
KOL Perspectives Perception of mirikizumab in moderatetosevere UCSummaryThis KOL Insight briefing focuses on KOLs views of mirikizumab in moderatetosevere UC.Questions topics Perception of Phase II...
View ArticleuBiome to Host Microbiome Conference in DavosKloster Switzerland in January
The leader in microbial genomics and 2018 Technology Pioneer announces they will host microbiome conference in Davos January 2019.SAN FRANCISCO PRWEB January 10 2019 uBiome the leader in microbial...
View ArticleVirtual Repurposing Can Speed the Discovery of New Uses for Existing Drugs
STAT News &8211; The process for discovering drugs tends to be based on the same kind of pigeonholing that doctors use to treat disease Parkinsons is one disease Crohns is something completely...
View ArticleDr. Christine Kaczmar Releases Controversial "Gut Check" Book
The first step to improving digestion is to understand why we get sick in the first place. Hint M.D.&39;s seldom reveal this. Once we recognize how the body becomes stressed we can effectively...
View ArticleRedx Pharma Plc REDX Pharmaceuticals Healthcare Deals and Alliances Profile...
Summary Redx Pharma Plc Redx Pharma formerly Redx Pharma Ltd is a drug discovery and development company that develops early stage and small molecule therapeutics. Redx Pharma uses its proven drug...
View ArticleuBiome Appoints Dr. Sarkis K. Mazmanian PhD MacArthur Genius and Luis & Nelly...
The leader in microbial genomics appoints renowned microbiologist and novel therapeutics developer to its board of scientific advisors.SAN FRANCISCO PRWEB January 14 2019 uBiome the leader in microbial...
View Article